Has Amy Amick received payments from drug or device companies?

Yes. Drug and device makers reported $6,332 in general payments to Amy Amick across 335 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amy Amick did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amy Amick come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amy Amick

Neurology · Peabody, MANPI 1790975829

Payments from drug & device makers

$6,332in general payments, 2019–2025

Across 335 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Biogen$861
Novartis$382
Teva Pharmaceuticals USA, Inc.$380
Bristol Myers Squibb$337
Sanofi$236
plus $3K from 39 others

What the payments were for

Speaking & faculty fees$952%
Food & beverage$6,23798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	70	$1,403
Biogen	46	$861
Novartis	23	$382
Teva Pharmaceuticals USA, Inc.	36	$380
Bristol Myers Squibb	31	$337
Sanofi	11	$236
Lilly USA, LLC	10	$196
Amgen	7	$178
SK Life Science, Inc.	7	$176
Acorda Therapeutics, Inc	7	$139
Avanir Pharmaceuticals, Inc.	5	$112
Pfizer	4	$110
UCB, Inc.	5	$108
Supernus Pharmaceuticals, Inc.	2	$103
Johnson & Johnson	4	$102
Acadia Pharmaceuticals Inc	5	$101
Sunovion Pharmaceuticals Inc.	5	$98
Biohaven Pharmaceuticals, Inc.	3	$98
Eisai Inc.	4	$95
GE HealthCare	4	$92
EMD Serono, Inc.	3	$86
Neurocrine Biosciences, Inc.	3	$79
Livanova USA, Inc.	4	$77
Kyowa Kirin, Inc.	3	$77
Biohaven Pharmaceutical Holding Company Ltd.	3	$75
AstraZeneca(2 entities)	3	$65
Amneal Pharmaceuticals LLC	3	$63
Genentech USA, Inc.	3	$56
Greenwich Biosciences, Inc.	2	$46
Avion Pharmaceuticals	2	$39
Ipsen Biopharmaceuticals, Inc	2	$38
MDD US Operations, LLC	2	$35
Argenx US, Inc.	1	$30
Cala Health, Inc.	1	$27
Lundbeck LLC	1	$26
Takeda Pharmaceuticals U.S.A., Inc.	1	$26
Banner Life Sciences, LLC	1	$24
Grifols USA, LLC	1	$23
Amylyx Pharmaceuticals, Inc.	1	$21
Neuropace, Inc.	1	$21
Merz North America, Inc.	1	$21
Otsuka America Pharmaceutical, Inc.	1	$20
Strongbridge US Inc.	1	$19
Catalyst Pharmaceuticals, Inc.	1	$17
TG Therapeutics, Inc.	1	$16

How this compares

$6,332 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl	16	$1,992
Carbidopa-LevodopaCarbidopa/Levodopa	21	$671
Levetiracetam	12	$418
Sumatriptan Succinate	11	$245
Donepezil Hcl	12	$178

Paid to pharmacies, not to this prescriber.

Other neurology in Peabody

Stephanie RutrickBoston$31.4M
Scott PlotkinBoston$26.3M
Patrick WenBoston$18.2M
James BerryBoston$8.9M
Isabel Arrillaga-RomanyBoston$8.2M
Donald MarksPlymouth$7.8M
Mahmut GurolBoston$7.4M
Gad MarshallBoston$6M
Shawn MurphyBoston$5.9M
Suma BabuBoston$5.8M

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →